Carteolol Hydrochloride

Sold as Cartrol, Ocupress. Every FDA application for this active ingredient: 2 branded and 3 generic.

As of Nov 15, 2026, FDA lists 5 applications for Carteolol Hydrochloride (sold as Cartrol, Ocupress), first approved Dec 28, 1988, with 0 new uses approved and 0 published complete response letters.

First approved: Dec 28, 1988
Applications: 5
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $421K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Carteolol HCl	Part D	$421K	-7%	5,171

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

CARTEOLOL HCL 1% EYE DROPS: $1.66 per MLGeneric · +10% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Dec 28, 1988	CartrolNDA 19204 · New molecular entity	Abbvie	2	Discontinued
May 23, 1990	OcupressNDA 19972 · New dosage form	Novartis	18	Discontinued
Jan 3, 2000	Carteolol HydrochlorideANDA 75476	Sandoz	5	Marketed
Jan 20, 2000	Carteolol HydrochlorideANDA 75546	Bausch And Lomb	7	Discontinued
Feb 6, 2002	Carteolol HydrochlorideANDA 76097	Apotex Inc	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA